Diabetes Research and Clinical Practice - Volume 120 - Supplement 1 - October 2016

207 / 244

Conclusions: The excess inflammatory response in the
adipose tissue and the formation of hepatic steatosis were
ameliorated by macrophage growth inhibition. In addition, the
inhibition of macrophage growth resulted in the suppression
of obesity-associated insulin resistance. These results suggest
that the local macrophage proliferation could be the common
pathophysiological feature in formation and progression of
dietary-induced insulin resistance and the formation of
hepatic steatosis.
PI-23
The weight changes of type 2 diabetes patients with non-
insulin antidiabetic drugs: a meta-analysis
Yifei CHEN1, Xiaoling CAI1, Wenjia YANG1, Xueying GAO1,
Xueyao HAN1, Linong JI1*. 1 Department of Endocrinology, Peking
University People ’s Hospital, China
This meta-analysis is to clarify the weight changes in type 2
diabetes mellitus (T2DM) patients with different non-insulin
antidiabetic treatment. Studies were identified by a literature
search of Medline, Embase, and others from the time that
recording commenced until December 2015. The meta-ana-
lysis was performed by computing the weighted mean
difference (WMD) and 95% confidence interval (CI) for a
change from baseline to the study endpoint for placebo
versus non-insulin antidiabetic drugs.
Totally 206 randomized controlled trials were judged to be
appropriate for inclusion in the meta-analysis. There is no
significant weight change from baseline (WMD −0.63 kg; p
\0.08) in the metformin group (2,353 participants) compare
with placebo. The alpha-glucosidase inhibitor group (2,424
participants) has a significantly greater decrease in the weight
change from baseline (WMD −0.53 kg; p\0.006) compare with
placebo. The Glucagon-like peptide-1 analogue group (5,246
participants) has a significantly greater decrease in the weight
change frombaseline (WMD −1.49 kg; p\0.00001) compare with
placebo. The sodium-glucose cotransporter 2 inhibitor group
(8,193 participants) has a significantly greater decrease in the
body weight (WMD −1.95 kg; p\0.00001) compare with placebo.
The dipeptidyl peptidase-4 inhibitor group (16,579 partici-
pants) has a significant increase in the body weight (WMD
0.25 kg; p\0.00001) compare with placebo. The thiazolidine-
dione group (7,768 participants) has a significantly greater
increase in the weight change from baseline (WMD 2.46 kg;
p\0.00001) compare with placebo. The sulphonylurea group
(1,768 participants) has a significantly greater increase in
weight change from baseline (WMD 2.23 kg; p\0.00001)
compare with placebo. According to this meta-analysis, the
weight changes in different treatments in type 2 diabetes were
comprehensively concluded.
PI-24
Association between adolescent pregnancy and sarcopenic
obesity in postmenopausal women: The KNHNES 2009 –2010
Jin Hwa KIM 1, Hyun Jin KIM2, Taeyoung YANG3,
Sangyong KIM1 *. 1Chosun University Hospital, 2Chungnam
National University Hospital, 3Taeyoung21 Hospital, Korea
Objective: The objective of the present study was to determine
whether there was an association between age at first
childbirth and sarcopenic obesity in postmenopausal women.
Research design and methods: This study was based on data
from the Korean National Health and Nutrition Examination
Survey (KNHANES), conducted by the Korean Ministry of
Health and Welfare, from 2009 to 2010. Out of 19,491
participants, the analysis included data for 2,196 postmeno-
pausal women. Subjects were subdivided according to their
age at first childbirth as follows: ≤ 19 years, 20–24 years, 25–29
years, and ≥30 years. Multivariate logistic regression analyses
were used to identify whether or not therewas an independent
association between the age of women at first childbirth and
sarcopenic obesity by adjusting for confounding factors.
Results: The prevalence rates of nonsarcopenic nonobesity,
nonsarcopenic obesity, sarcopenic nonobesity, and sarcopenic
obesity were 48.6%, 16.1%, 15.0%, and 20.3%, respectively.
Sarcopenic obesity prevalence differed significantly between
the subgroups and increased with earlier age at first childbirth,
with 11.7% in subjects ≥30 years at first childbirth and 30.7% in
subjects ≤19 years at first childbirth. After fully adjusting for
confounding factors, including chronic diseases, sociodemo-
graphic influences, lifestyle differences, serum 25(OH)D levels,
and reproductive issues, women ≤19 years at first childbirth
were significantly associated with sarcopenic obesity (odds
ratio [OR] 1.719 [95% CI 1.091–2.711]).
Conclusions: Women’s age at first childbirth influenced the
sarcopenic obesity risk in postmenopausal women, and
adolescent pregnancy was independently associated with a
higher risk of sarcopenic obesity in postmenopausal women.
PI-25
Hinokitiol improves insulin action in 3T3-L1 adipocytes
Yun-Hsuan WU1, Kai-Li LIU1*. 1Department of Nutrition, School of
Medical Laboratory and Biotechnology Chung Shan Medical
University, Taiwan
In recent decades, obesity has become a worldwide epidemic
disease. Obesity leads to chronic inflammation and insulin
resistance which are associated with the development of type
2 diabetes mellitus, hypertension and cardiovascular disease.
Hinokitiol, a phytochemical isolated from Chamaecyparis
obtusa Siebold & Zucc. var. formosana (Hayatya) Rehder, has
shown anti-cancer, anti-bacterial and anti-inflammatory
functions. Previous data of ours have demonstrated that
Hinokitiol decreases adipogenesis as evidenced by reduction
of lipid droplets and triglyceride level as well as modulation of
adipogenesis related marker expression. Although Hinokitiol
reduces adipogenesis, effect of Hinokitiol especially in insulin
action on differentiated 3T3-L1 adipocytes is not clear.
Differentiated 3T3-L1 adipocytes treated with test concentra-
tion of Hinokitiol of up to 5 μ M still had more than 90% of the
cell viability of cultures treated with Dimethyl sulfoxide
vehicle control. Moreover, Hinokitiol did not change the
mRNA expression of of peroxisome proliferator-activated
receptor γ, glucose transporter type 4 (GLUT4), adipocyte
protein 2 and adiponectin in differentiated 3T3-L1 adipocytes.
Notably, pre-treated with Hinokitiol significantly improve
insulin action in differentiated 3T3-L1 adipocytes.
Specifically, insulin-induced protein kinase B and Akt sub-
strate of 160 kDa phosphorylation and membrane GLUT4
protein expression as well as glucose uptake is enhanced by
Hinokitiol treatment. Based on these above findings,
Hinokitiol may improve adipocytes insulin action and have a
health benefits on obesity related insulin resistance.
PI-26
Prebariatric screening for diabetes and cardiovascular risk in
an interdisciplinary obesity center discloses unexpected
gender differences
Kristian RETT1,3*, Lennart SCHMIDT1, Anna BUCKENMAYER1,
Erika FISCHER1,3, Kathrin RÖVENICH1,3, Elke WEITZ1,3 ,
Plamen STAIKOV2,3, Klara STEIN1,3. 1Department for
Endocrinology and Diabetes, Krankenhaus Sachsenhausen,
2Department for Surgery and Bariatric Surgery, Krankenhaus
Sachsenhausen, 3German Obesity Center, Frankfurt, Germany
Question: Type 2 diabetes prevalence is higher in men, but
diabetic women lose more years of life. Obesity prevalence is
only slightly higher, but bariatric obesity treatment is much
more frequent in women. We therefore performed a gender-
specific evaluation of both systematic diabetes screening and
atherosclerotic cardiovascular risk assessment in an obese
cohort qualifying for bariatric surgery.
Methods:315 consecutive patients (65%women) who qualified
for bariatric surgery according to current guidelines and a local
Poster Presentations / Diabetes Research and Clinical Practice 120S1 (2016) S65–S211 S189